1. The rapid absorption of Afrezza achieves Tmax in ___ to ___ minutes, compared with approximately 40 minutes with subcutaneously administered rapid-acting insulin analog.
A. 12, 15
B. 20, 25
C. 30, 40
D. 40, 50
2. Which of the following SGLT-2 inhibitors is recommended for use in patients with an eGFR <45 mL/min/1.73 m2:
A. Canagliflozin
B. Dapagliflozin
C. Empagliflozin
D. None of the above
3. Which of the following antihyperglycemic medications is not recommended for use in people with chronic lung disease or in those who smoke tobacco:
A. Insulin glargine U-300
B. Technosphere insulin
C. Dulaglutide
D. Albiglutide
4. Which of the following long-acting GLP-1 RAs is commercially available in prefilled pens as a solution, thus not requiring reconstitution and mixing prior to injection:
A. Albiglutide
B. Exenatide ER
C. Dulaglutide
D. None of the above products is available in prefilled pens
5. For which class of medications should patients be counseled to report symptoms suggestive of thyroid tumors:
A. Inhaled insulin
B. GLP-1 receptor agonists
C. SGLT-2 inhibitors
D. None of the above
6. Which of the following medication classes was recently linked to case reports of euglycemic diabetic ketoacidosis (eDKA):
A. DPP-4 inhibitors
B. GLP-1 receptor agonists
C. SGLT-2 inhibitors
D. Ultra-long-acting insulins
7. Which of the following would not be an appropriate counseling point for a patient receiving a prescription for a Toujeo SoloStar pen:
A. Explain that the Toujeo SoloStar pen contains a concentrated form of insulin that requires that the patient divide their prescribed insulin dose by 3.
B. Inform patients the most common adverse reactions to expect include hypoglycemia, injection site reactions, lipodystrophy, edema, and weight gain.
C. Instruct patients on the continued need for blood glucose monitoring and appropriate management of hypoglycemic and hyperglycemic episodes.
D. Instruct patients to never share their Toujeo SoloStar pen, even if needles are changed.
8. Which of the following agents achieves a long duration of action via fusion of the drug to human albumin:
A. Albiglutide
B. Dulaglutide
C. Insulin glargine; U-300
D. Insulin degludec
9. Which of the following statements is false regarding insulin glargine; U-300:
A. When converting someone from U-100 insulin glargine to U-300, a 1:1 ratio can be used.
B. A common side effect associated with U-300 insulin glargine use is hypoglycemia.
C. Toujeo is only available commercially in a prefilled Toujeo SoloStar pen.
D. Patients generally require fewer units of U-300 to achieve glycemic control when compared to U-100 insulin glargine.
10. All of the following adverse reactions could be expected with SGLT-2 inhibitor use except :
A. Urinary tract infections
B. Hypertension
C. Genital mycotic infections
D. Orthostasis
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
21. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
22. Will the information presented cause you to change your practice?
A. Yes
B. No
23. Are you committed to making these changes?
A. Yes
B. No
24. As a result of this activity, did you learn something new?
A. Yes
B. No
25. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
26. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20
E. >20
